Search the Newsreel

Intellia Sets Aug. 6 Webcast for Second-Quarter Business Update

Intellia Therapeutics Inc (NTLA) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Intellia Therapeutics Inc's (NTLA) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years, indicating no recent dividend payouts. The page also presents general financial information for NTLA, …

Form 4 Intellia Therapeutics Inc For: 24 July By Investing.com

This article reports on a Form 4 filing for Intellia Therapeutics Inc (NTLA) dated July 24. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a material change in the holdings of …

Intellia Therapeutics CFO sells $91,248 in stock By Investing.com

Intellia Therapeutics' CFO, Edward J. Dulac III, sold 8,111 shares of the company's common stock for $91,248. This "sell-to-cover" transaction was non-discretionary, meant to satisfy tax obligations upon restricted stock unit vesting. The stock has recently declined by 6%, but InvestingPro data suggests it …

Intellia Therapeutics (NTLA) CFO logs 8,111-share sell-to-cover tax trade

Intellia Therapeutics' EVP and CFO, Edward J. Dulac III, executed a mandatory "sell-to-cover" transaction of 8,111 shares of common stock on July 22, 2026. This sale, at a weighted average price of $11.25, was conducted to satisfy tax withholding obligations arising from RSU vesting …

Intellia Therapeutics Stock Short Interest Falls to 44.41%

The short interest in Intellia Therapeutics (NASDAQ:NTLA) saw a notable decrease during the first half of July, with a 44.41% drop to 5,500,000 shares. This translates to an average of 1.0 days to cover these positions, indicating a significant change in investor sentiment or …

Intellia Therapeutics Stock And 2 High Growth Shares With Strong Balance Sheets

This article identifies three high-growth companies—Intellia Therapeutics (NTLA), Insulet (PODD), and Hamilton Lane (HLNE)—that also possess strong balance sheets, as highlighted by Simply Wall St's "Healthy high growth potential" screener. Each company is analyzed for its operations, market cap, and key investment drivers, as …

Intellia Stock And 2 Growth Shares With Clear Earnings Upside

This article highlights three growth stocks—Intellia Therapeutics (NTLA), Insulet (PODD), and Hamilton Lane (HLNE)—identified by a "Healthy high growth potential" screener. These companies are characterized by strong earnings growth forecasts and solid financial positions. While each presents significant opportunities, they also carry distinct risks …

Intellia Therapeutics (NTLA) Resumes Key Trials, Is The Undervalued Case Still Convincing?

Intellia Therapeutics has resumed its MAGNITUDE and MAGNITUDE-2 trials after the FDA lifted clinical holds, allowing patient enrollment for its CRISPR programs to continue. Despite a recent share price decline, the stock is considered 51% undervalued with a fair value of $26.63, underpinned by …

Intellia stock downgraded by Wolfe Research on valuation concerns

Wolfe Research downgraded Intellia Therapeutics (NASDAQ:NTLA) to Underperform from Peerperform, setting a price target of $9.00 due to valuation concerns. The firm based its valuation on lonvo-z supporting the company if nex-z is written off, projecting lower cumulative revenue compared to consensus estimates. Intellia, …

Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound?

NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Intellia Therapeutics (NTLA) Is Down 15.1% After Phase 3 lonvo-z Data And $180M Equity Raise - Has The Bull Case Changed?

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates

Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates